Plus Therapeutics (NASDAQ:CNSY) Upgraded by Zacks Research to Hold Rating

Plus Therapeutics (NASDAQ:CNSY) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Separately, Weiss Ratings initiated coverage on shares of Plus Therapeutics in a report on Tuesday, August 4th. They set a “sell (e+)” rating for the company. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Plus Therapeutics currently has an average rating of “Reduce”.

Plus Therapeutics Stock Performance

Shares of Plus Therapeutics stock opened at $2.94 on Tuesday. The company has a market cap of $22.31 million, a P/E ratio of -0.88 and a beta of 1.39. Plus Therapeutics has a 1 year low of $2.62 and a 1 year high of $23.42.

Plus Therapeutics (NASDAQ:CNSY) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.35). Plus Therapeutics had a negative net margin of 620.70% and a negative return on equity of 394.17%. Equities research analysts forecast that Plus Therapeutics will post -3.76 EPS for the current year.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.